Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
, 9 (5), 567-8

Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?

Affiliations
Editorial

Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?

Chang Soo Eun et al. Gut Liver.

Comment on

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

References

    1. Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27. doi: 10.5009/gnl14226. - DOI - PMC - PubMed
    1. Seo HI, Park DI, Kim TO, et al. The effect of infliximab on patients with ulcerative colitis in Korea. Intest Res. 2014;12:214–220. doi: 10.5217/ir.2014.12.3.214. - DOI - PMC - PubMed
    1. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18:212–218. doi: 10.1002/ibd.21680. - DOI - PubMed
    1. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther. 2013;38:294–302. doi: 10.1111/apt.12375. - DOI - PubMed
    1. Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis. 2013;28:287–293. doi: 10.1007/s00384-012-1602-8. - DOI - PubMed
Feedback